Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Details

Connection

Enrique Alvarez to Multiple Sclerosis

This is a "connection" page, showing publications Enrique Alvarez has written about Multiple Sclerosis.

 
Connection Strength
  
 
 
8.598
  
  1. Alvarez E, Longbrake EE, Rammohan KW, Stankiewicz J, Hersh CM. Secondary hypogammaglobulinemia in patients with multiple sclerosis on anti-CD20 therapy: Pathogenesis, risk of infection, and disease management. Mult Scler Relat Disord. 2023 Nov; 79:105009.
    View in: PubMed
    Score: 0.534
  2. Abdelrahman A, Alvarez E. Advances in Multiple Sclerosis Neurotherapeutics, Neuroprotection, and Risk Mitigation Strategies. Neurol Clin. 2024 Feb; 42(1):115-135.
    View in: PubMed
    Score: 0.534
  3. Alvarez E, Nair KV, Tan H, Rathi K, Gabler NB, Maiese EM, Deshpande C, Shao Q. Real-world cost of care and site of care in patients with multiple sclerosis initiating infused disease-modifying therapies. J Med Econ. 2023 Jan-Dec; 26(1):494-502.
    View in: PubMed
    Score: 0.509
  4. Alvarez E, Nair KV, Hoyt BD, Seale RA, Sillau S, Miravalle A, Engebretson E, Schurr B, Corboy JR, Vollmer TL, Honce JM. Brain atrophy rates in patients with multiple sclerosis on long term natalizumab resembles healthy controls. Mult Scler Relat Disord. 2021 Oct; 55:103170.
    View in: PubMed
    Score: 0.461
  5. Wolf AB, Ryerson LZ, Pandey K, McGettigan BM, Vollmer T, Corboy JR, Alvarez E. Rituximab-induced serum sickness in multiple sclerosis patients. Mult Scler Relat Disord. 2019 Nov; 36:101402.
    View in: PubMed
    Score: 0.405
  6. Vollmer BL, Nair KV, Sillau S, Corboy JR, Vollmer T, Alvarez E. Natalizumab versus fingolimod and dimethyl fumarate in multiple sclerosis treatment. Ann Clin Transl Neurol. 2019 02; 6(2):252-262.
    View in: PubMed
    Score: 0.384
  7. Weinkle L, Domen CH, Shelton I, Sillau S, Nair K, Alvarez E. Exploring cannabis use by patients with multiple sclerosis in a state where cannabis is legal. Mult Scler Relat Disord. 2019 Jan; 27:383-390.
    View in: PubMed
    Score: 0.383
  8. Alvarez E, Mowry EM. We need to conduct clinical trials of disease-modifying therapy in pregnancy to optimize care of women with MS - Yes. Mult Scler. 2019 02; 25(2):187-188.
    View in: PubMed
    Score: 0.381
  9. Vollmer B, Honce JM, Sillau S, Corboy JR, Vollmer T, Nair K, Alvarez E. The impact of very short transition times on switching from Natalizumab to Fingolimod on imaging and clinical effectiveness outcomes in multiple sclerosis. J Neurol Sci. 2018 07 15; 390:89-93.
    View in: PubMed
    Score: 0.367
  10. Alvarez E. Should we start evaluating intrathecal IgM production clinically? Eur J Neurol. 2015 Aug; 22(8):1143-4.
    View in: PubMed
    Score: 0.292
  11. Alvarez E, Piccio L, Mikesell RJ, Klawiter EC, Parks BJ, Naismith RT, Cross AH. CXCL13 is a biomarker of inflammation in multiple sclerosis, neuromyelitis optica, and other neurological conditions. Mult Scler. 2013 Aug; 19(9):1204-8.
    View in: PubMed
    Score: 0.255
  12. Wu GF, Alvarez E. The immunopathophysiology of multiple sclerosis. Neurol Clin. 2011 May; 29(2):257-78.
    View in: PubMed
    Score: 0.227
  13. Scharf A, Cohen JA, Marrie RA, Miller AE, Waubant E, Kilbane M, Luskin E, Azevedo CJ, Dever M, Alvarez E, Calabresi PA, Chahin S, Freeman L, Nakamura K, Longbrake EE, Mowry EM, Oh J, Rodrigues PR, Ramos M, Sotirchos ES, Cutter GR, Kaisey M, Amin M, Toljan K, Illenberger N, Bilello M, Lee J, Maya M, Obusez EC, Schindler MK, Suthiphosuwan S, Ulano A, Shinohara RT, Reich DS, Solomon AJ, Sicotte NL, Sati P, Ontaneda D. Application of the 2024 McDonald Criteria in Individuals With Nonspecific Symptoms or Incidental Imaging Findings in a Multicenter Study. Neurology. 2026 Jul 14; 107(1):e218183.
    View in: PubMed
    Score: 0.162
  14. Van Laethem D, Costers L, Miravalle A, Alvarez E, Myers B, Boster A, Al Halawani H, Dewil M, Cambron M, Grothe M, Denissen S, Bartz R, Sima D, Ribbens A, Smeets D, Nagels G. The relationship between objective and subjective cognitive performance and clinical and MRI disease burden in early multiple sclerosis. Sci Rep. 2026 May 16; 16(1).
    View in: PubMed
    Score: 0.161
  15. Apeltsin L, Asokan S, Freitas B, Karekar K, Guzman S, Alvarez E, Yu X. Multiplex Detection of Immunoglobulins Uncovers Intrathecal IgA Elevation in Multiple Sclerosis. Cells. 2026 May 10; 15(10).
    View in: PubMed
    Score: 0.161
  16. Asokan S, Zhou W, Fringuello A, Pointon T, Kennedy A, Freitas B, Tumas French J, Zhao H, Coughlan C, Alvarez E, Yu X. CNS-compartmentalized IgG aggregates and glycosylation in multiple sclerosis contribute to oligoclonal bands and neuronal cytotoxicity. Front Immunol. 2026; 17:1689835.
    View in: PubMed
    Score: 0.159
  17. Henry M, Crompton T, Alvarez E, Enoka RM. Impaired force control and muscle activation during isometric contractions in people with multiple sclerosis. J Electromyogr Kinesiol. 2026 Apr; 87:103124.
    View in: PubMed
    Score: 0.158
  18. Ghezzi L, Kosa P, Greenwood M, Alvarez E, Freedman CL, Cross AH, Pace F, Freedman MS, Kocot J, Piccio L, Bielekova B. From Diagnosis to Disease Staging: Multisite Validation of Cerebrospinal Fluid Molecular Tests in Multiple Sclerosis. Ann Neurol. 2026 02; 99(2):328-340.
    View in: PubMed
    Score: 0.154
  19. Quinn CM, Rajarajan P, Gill AJ, Kopinsky H, Wolf AB, de Camargo CS, Lamb J, Bacon TE, Murray JC, Probasco JC, Galetta KM, Kantor D, Coyle P, Bhise V, Alvarez E, Conway SE, Bhattacharyya S, Kister I. Neurologic Outcomes in People With Multiple Sclerosis Treated With Immune Checkpoint Inhibitors for Oncologic Indications. Neurology. 2024 Dec 10; 103(11):e210003.
    View in: PubMed
    Score: 0.145
  20. Mañago MM, Cohen ET, Alvarez E, Hager ER, Owens JG, Bade M. Feasibility of Low-Load Resistance Training Using Blood Flow Restriction for People With Advanced Multiple Sclerosis: A Prospective Cohort Study. Phys Ther. 2024 01 01; 104(1).
    View in: PubMed
    Score: 0.136
  21. Wolf AB, Alvarez E, Corboy JR. Comparative Efficacy of Disease-Modifying Treatments for Relapsing Multiple Sclerosis-Variations in Real-World Experience. JAMA Neurol. 2024 01 01; 81(1):87.
    View in: PubMed
    Score: 0.136
  22. Col NF, Solomon AJ, Alvarez E, Pbert L, Ionete C, BerriosMorales I, Chester J, Kutz C, Iwuchukwu C, Livingston T, Springmann V, Col HV, Ngo LH. Implementing Shared Decision-Making for Multiple Sclerosis: The MS-SUPPORT Tool. Mult Scler Relat Disord. 2023 Dec; 80:105092.
    View in: PubMed
    Score: 0.135
  23. Zhou W, Graner M, Beseler C, Domashevich T, Selva S, Webster G, Ledreux A, Zizzo Z, Lundt M, Alvarez E, Yu X. Plasma IgG aggregates as biomarkers for multiple sclerosis. Clin Immunol. 2023 11; 256:109801.
    View in: PubMed
    Score: 0.134
  24. Zhou W, Graner M, Paucek P, Beseler C, Boisen M, Bubak A, Asturias F, George W, Graner A, Ormond D, Vollmer T, Alvarez E, Yu X. Multiple sclerosis plasma IgG aggregates induce complement-dependent neuronal apoptosis. Cell Death Dis. 2023 04 08; 14(4):254.
    View in: PubMed
    Score: 0.130
  25. Courter RJ, Alvarez E, Enoka RM, Ahmed AA. Metabolic costs of walking and arm reaching in persons with mild multiple sclerosis. J Neurophysiol. 2023 04 01; 129(4):819-832.
    View in: PubMed
    Score: 0.129
  26. Barrera B, Simpson H, Engebretson E, Sillau S, Valdez B, Parra-González J, Winger RC, Epperson LA, Banks A, Pierce K, Spotts M, O'Gean K, Alvarez E, Gross R, Piquet AL, Schreiner T, Corboy JR, Pei J, Vollmer TL, Nair KV. Safety and patient experience with at-home infusion of ocrelizumab for multiple sclerosis. Ann Clin Transl Neurol. 2023 04; 10(4):579-588.
    View in: PubMed
    Score: 0.129
  27. Longbrake EE, Hua LH, Mowry EM, Gauthier SA, Alvarez E, Cross AH, Pei J, Priest J, Raposo C, Hafler DA, Winger RC. The CELLO trial: Protocol of a planned phase 4 study to assess the efficacy of Ocrelizumab in patients with radiologically isolated syndrome. Mult Scler Relat Disord. 2022 Dec; 68:104143.
    View in: PubMed
    Score: 0.124
  28. Ziemssen T, Arnold DL, Alvarez E, Cross AH, Willi R, Li B, Kukkaro P, Kropshofer H, Ramanathan K, Merschhemke M, Kieseier B, Su W, Häring DA, Hauser SL, Kappos L, Kuhle J. Prognostic Value of Serum Neurofilament Light Chain for Disease Activity and Worsening in Patients With Relapsing Multiple Sclerosis: Results From the Phase 3 ASCLEPIOS I and II Trials. Front Immunol. 2022; 13:852563.
    View in: PubMed
    Score: 0.121
  29. Alenazy M, Daneshgar Asl S, Petrigna L, Feka K, Alvarez E, Almuklass AM, Enoka RM. Treatment with electrical stimulation of sensory nerves improves motor function and disability status in persons with multiple sclerosis: A pilot study. J Electromyogr Kinesiol. 2021 Dec; 61:102607.
    View in: PubMed
    Score: 0.117
  30. Ziemssen T, Giovannoni G, Alvarez E, Bhan V, Hersh C, Hoffmann O, Oreja-Guevara C, Robles-Cedeño RR, Trojano M, Vermersch P, Dobay P, Khwaja M, Stadler B, Rauser B, Hach T, Piani-Meier D, Burton J. Multiple Sclerosis Progression Discussion Tool Usability and Usefulness in Clinical Practice: Cross-sectional, Web-Based Survey. J Med Internet Res. 2021 10 06; 23(10):e29558.
    View in: PubMed
    Score: 0.117
  31. Bar-Or A, Wiendl H, Montalban X, Alvarez E, Davydovskaya M, Delgado SR, Evdoshenko EP, Giedraitiene N, Gross-Paju K, Haldre S, Herrman CE, Izquierdo G, Karelis G, Leutmezer F, Mares M, Meca-Lallana JE, Mickeviciene D, Nicholas J, Robertson DS, Sazonov DV, Sharlin K, Sundaram B, Totolyan N, Vachova M, Valis M, Bagger M, Häring DA, Ludwig I, Willi R, Zalesak M, Su W, Merschhemke M, Fox EJ. Rapid and sustained B-cell depletion with subcutaneous ofatumumab in relapsing multiple sclerosis: APLIOS, a randomized phase-2 study. Mult Scler. 2022 05; 28(6):910-924.
    View in: PubMed
    Score: 0.117
  32. Enoka RM, Almuklass AM, Alenazy M, Alvarez E, Duchateau J. Distinguishing between Fatigue and Fatigability in Multiple Sclerosis. Neurorehabil Neural Repair. 2021 11; 35(11):960-973.
    View in: PubMed
    Score: 0.117
  33. Kline PW, Christiansen CL, Hager ER, Alvarez E, Mañago MM. Movement compensations during a step ascent task are associated with stair climbing performance in people with multiple sclerosis. Gait Posture. 2021 06; 87:27-32.
    View in: PubMed
    Score: 0.113
  34. Nicholas JA, Shin RK, Alvarez E, Hendin B, Nair KV, Lublin FD. Pandemic forward: Lessons learned and expert perspectives on multiple sclerosis care in the COVID-19 era. Mult Scler Relat Disord. 2021 04; 49:102715.
    View in: PubMed
    Score: 0.111
  35. Vollmer TL, Cohen JA, Alvarez E, Nair KV, Boster A, Katz J, Pardo G, Pei J, Raut P, Merchant S, MacLean E, Pradhan A, Moss B. Safety results of administering ocrelizumab per a shorter infusion protocol in patients with primary progressive and relapsing multiple sclerosis. Mult Scler Relat Disord. 2020 Nov; 46:102454.
    View in: PubMed
    Score: 0.108
  36. Vollmer BL, Wallach AI, Corboy JR, Dubovskaya K, Alvarez E, Kister I. Serious safety events in rituximab-treated multiple sclerosis and related disorders. Ann Clin Transl Neurol. 2020 09; 7(9):1477-1487.
    View in: PubMed
    Score: 0.108
  37. Mañago MM, Kline PW, Alvarez E, Christiansen CL. Trunk and pelvis movement compensation in people with multiple sclerosis: Relationships to muscle function and gait performance outcomes. Gait Posture. 2020 05; 78:48-53.
    View in: PubMed
    Score: 0.105
  38. Almuklass AM, Capobianco RA, Feeney DF, Alvarez E, Enoka RM. Sensory nerve stimulation causes an immediate improvement in motor function of persons with multiple sclerosis: A pilot study. Mult Scler Relat Disord. 2020 Feb; 38:101508.
    View in: PubMed
    Score: 0.102
  39. Zivadinov R, Medin J, Khan N, Korn JR, Chitnis T, Naismith RT, Alvarez E, Dwyer MG, Bergsland N, Carl E, Silva D, Weinstock-Guttman B. Impact of fingolimod on clinical and magnetic resonance imaging outcomes in routine clinical practice: A retrospective analysis of the multiple sclerosis, clinical and MRI outcomes in the USA (MS-MRIUS) study. Mult Scler Relat Disord. 2019 Jan; 27:65-73.
    View in: PubMed
    Score: 0.095
  40. Zivadinov R, Medin J, Khan N, Korn JR, Bergsland N, Dwyer MG, Chitnis T, Naismith RT, Alvarez E, Kinkel P, Cohan S, Hunter SF, Silva D, Weinstock-Guttman B. Fingolimod's Impact on MRI Brain Volume Measures in Multiple Sclerosis: Results from MS-MRIUS. J Neuroimaging. 2018 07; 28(4):399-405.
    View in: PubMed
    Score: 0.092
  41. Col NF, Solomon AJ, Springmann V, Garbin CP, Ionete C, Pbert L, Alvarez E, Tierman B, Hopson A, Kutz C, Berrios Morales I, Griffin C, Phillips G, Ngo LH. Whose Preferences Matter? A Patient-Centered Approach for Eliciting Treatment Goals. Med Decis Making. 2018 01; 38(1):44-55.
    View in: PubMed
    Score: 0.088
  42. Chen D, Ireland SJ, Remington G, Alvarez E, Racke MK, Greenberg B, Frohman EM, Monson NL. CD40-Mediated NF-?B Activation in B Cells Is Increased in Multiple Sclerosis and Modulated by Therapeutics. J Immunol. 2016 12 01; 197(11):4257-4265.
    View in: PubMed
    Score: 0.083
  43. Tallantyre EC, Planchon SM, Howard H, Mays J, Frowd N, Cohen JA, Coles A, Hersh CM, Miller DM, Dever M, Gray EH, LaRocca NG, Nakamura K, Bale C, Covey-Crump G, Alvarez E, Arun T, Brownlee WJ, Craner M, Freeman L, Frost N, Goldman MD, Gupta RK, Harding KE, Hobart J, Hutton GJ, Hyland MH, Kalra S, Kannan M, Kantarci O, Lashley D, Lily O, Mahad D, Nicholas JA, Nicholas R, Paling D, Pearson OR, Rice CM, Samudralwar R, Schmalstieg WF, Singh M, Zune The E, Weinstock-Guttman B, Zabeti A, Love TE, Gunzler DD, Liu Y, Gerry S, Evangelou N, Ontaneda D. Disease-modifying treatment preferences and decision-making in a multiple sclerosis randomized and observational clinical trial (DELIVER-MS). Mult Scler. 2026 Jun; 32(7):722-736.
    View in: PubMed
    Score: 0.040
  44. Gross PS, Durán-Laforet V, Ho LT, Melchor GS, Zia S, Manavi Z, Barclay WE, Lee SH, Shults N, Selva S, Alvarez E, Plemel JR, Fu MM, Schafer DP, Huang JK. Senescent-like microglia limit remyelination through the senescence associated secretory phenotype. Nat Commun. 2025 Mar 07; 16(1):2283.
    View in: PubMed
    Score: 0.037
  45. Steinman L, Fox E, Hartung HP, Alvarez E, Qian P, Wray S, Robertson D, Huang D, Selmaj K, Wynn D, Cutter G, Mok K, Hsu Y, Xu Y, Weiss MS, Bosco JA, Power SA, Lee L, Miskin HP, Cree BAC. Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis. N Engl J Med. 2022 08 25; 387(8):704-714.
    View in: PubMed
    Score: 0.031
  46. Qian P, Lancia S, Alvarez E, Klawiter EC, Cross AH, Naismith RT. Association of neuromyelitis optica with severe and intractable pain. Arch Neurol. 2012 Nov; 69(11):1482-7.
    View in: PubMed
    Score: 0.016
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2026 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)